Platelets release mitochondrial antigens in systemic lupus erythematosus

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Autoantibodies against DNA and nuclear components are central to systemic lupus erythematosus (SLE) pathophysiology.
• The precise origins of circulating autoantigens in SLE remain largely unidentified.
• Platelets are increasingly recognized for their role in immune responses and inflammation.

Purpose of the Study:

• To investigate the role of platelets in releasing mitochondrial components as autoantigens in SLE.
• To elucidate the mechanisms underlying platelet-mediated mitochondrial release in SLE.
• To explore the potential of targeting platelets for SLE therapy.

Main Methods:

• Analysis of mitochondrial DNA and extracellular mitochondria in SLE patient blood samples.
• Assessment of platelet degranulation and FcγRIIA stimulation.
• Utilizing transgenic mice expressing FcγRIIA for in vivo studies.
• Employing reporter mice to track mitochondrial release from platelets.

Main Results:

• Platelets in SLE patients release mitochondrial DNA associated with extracellular mitochondria.
• Mitochondrial release strongly correlates with platelet degranulation.
• FcγRIIA activation on platelets is crucial for this process.
• In vivo studies confirmed FcγRIIA-driven platelet recruitment and in vivo mitochondrial release.

Conclusions:

• Platelets are a significant source of extracellular mitochondria and mitochondrial DNA in SLE.
• FcγRIIA signaling on platelets drives the release of these autoantigens.
• Platelets represent a promising therapeutic target for managing SLE.